{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:35:55Z","timestamp":1770824155625,"version":"3.50.1"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,1,15]]},"abstract":"<jats:p> PURPOSE: Melastatin (MLSN-1), a novel melanocyte-specific gene recently identified using a genomic approach, is expressed in murine and human melanoma cells at levels inversely proportional to metastatic rates in vivo. We studied the relationship between expression of melastatin mRNA in the primary cutaneous tumor and prognosis in patients with localized malignant melanoma. <\/jats:p><jats:p> PATIENTS AND METHODS: Melastatin mRNA was evaluated by in situ hybridization in primary cutaneous melanoma from 150 patients with localized disease (American Joint Committee on Cancer [AJCC] stage I and II). Multivariate Cox proportional hazards regression analysis was performed to assess the prognostic utility of melastatin mRNA expression while adjusting for other prognostic indicators. <\/jats:p><jats:p> RESULTS: Uniform melastatin mRNA expression in the primary tumor was correlated with prolonged disease-free survival (P &lt; .0001). Multivariate analysis revealed that melastatin status, mitotic rate, and tumor thickness influence disease-free survival independently. The 8-year disease-free survival rate in AJCC stage I patients whose tumors diffusely expressed melastatin mRNA was 100%, whereas in stage I patients with melastatin loss, the disease-free survival rate was 77% \u00b1 15% (median \u00b1 SE). In patients with stage II disease whose tumors diffusely expressed melastatin mRNA, the 8-year disease-free survival rate was 90% \u00b1 7%, whereas in patients with melastatin loss, the disease-free survival rate was 51% \u00b1 8%. <\/jats:p><jats:p> CONCLUSION: Downregulation of melastatin mRNA in the primary cutaneous tumor is a prognostic marker for metastasis in patients with localized malignant melanoma and is independent of tumor thickness and other variables. Used in combination, melastatin status and tumor thickness allow for the identification of subgroups of patients at high and low risk of developing metastatic disease. <\/jats:p>","DOI":"10.1200\/jco.2001.19.2.568","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:36:55Z","timestamp":1487921815000},"page":"568-576","source":"Crossref","is-referenced-by-count":171,"title":["Melastatin Expression and Prognosis in Cutaneous Malignant Melanoma"],"prefix":"10.1200","volume":"19","author":[{"given":"Lyn M.","family":"Duncan","sequence":"first","affiliation":[{"name":"From the Dermatopathology Unit and Departments of Pathology and Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston; and Millennium Predictive Medicine, Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Deeds","sequence":"additional","affiliation":[{"name":"From the Dermatopathology Unit and Departments of Pathology and Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston; and Millennium Predictive Medicine, Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank E.","family":"Cronin","sequence":"additional","affiliation":[{"name":"From the Dermatopathology Unit and Departments of Pathology and Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston; and Millennium Predictive Medicine, Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Donovan","sequence":"additional","affiliation":[{"name":"From the Dermatopathology Unit and Departments of Pathology and Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston; and Millennium Predictive Medicine, Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur J.","family":"Sober","sequence":"additional","affiliation":[{"name":"From the Dermatopathology Unit and Departments of Pathology and Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston; and Millennium Predictive Medicine, Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kauffman","sequence":"additional","affiliation":[{"name":"From the Dermatopathology Unit and Departments of Pathology and Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston; and Millennium Predictive Medicine, Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette J.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"From the Dermatopathology Unit and Departments of Pathology and Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston; and Millennium Predictive Medicine, Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-083517","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.46.4.195"},{"key":"R2-083517","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90041-9"},{"key":"R3-083517","doi-asserted-by":"publisher","DOI":"10.1002\/ssu.2980080611"},{"key":"R5-083517","doi-asserted-by":"crossref","unstructured":"Parker  SL,   Tong  T,   Bolden  S,  et al:  Cancer statistics:   1996.   CA Cancer J Clin 46:  7,1996-29,","DOI":"10.3322\/canjclin.46.1.5"},{"key":"R6-083517","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.46.4.225"},{"key":"R7-083517","unstructured":"Duncan  L,   Deeds  J,   Hunter  J,  et al:  Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis.   Cancer Res 58:  1515,1998-1520,"},{"key":"R8-083517","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.24.1893"},{"key":"R9-083517","doi-asserted-by":"publisher","DOI":"10.1080\/028418699431113"},{"key":"R10-083517","unstructured":"Duncan  LM:   Prognostic indicators in melanoma.   Adv Dermatol 15:  489,1999-517,"},{"key":"R11-083517","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197011000-00017"},{"key":"R12-083517","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5"},{"key":"R13-083517","doi-asserted-by":"publisher","DOI":"10.1159\/000011967"},{"key":"R14-083517","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2391::AID-CNCR14>3.0.CO;2-I"},{"key":"R15-083517","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.1996.0242"},{"key":"R16-083517","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(94)00222-Z"},{"key":"R17-083517","doi-asserted-by":"publisher","DOI":"10.1210\/endo.137.11.8895385"},{"key":"R18-083517","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(00)80003-9"},{"key":"R19-083517","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1998.5549"},{"key":"R20-083517","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.2.203"},{"key":"R21-083517","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1998.5551"},{"key":"R22-083517","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(199807)176:1<196::AID-JCP21>3.0.CO;2-4"},{"key":"R23-083517","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006594318633"},{"key":"R24-083517","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.38.24884"},{"key":"R25-083517","doi-asserted-by":"publisher","DOI":"10.1038\/nm0695-534"},{"key":"R26-083517","doi-asserted-by":"publisher","DOI":"10.1038\/31965"},{"key":"R27-083517","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800615)45:12<3012::AID-CNCR2820451223>3.0.CO;2-O"},{"key":"R28-083517","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3207(18)30318-1"},{"key":"R29-083517","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-5-199609010-00003"},{"key":"R30-083517","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<427::AID-CNCR8>3.0.CO;2-G"},{"key":"R31-083517","doi-asserted-by":"publisher","DOI":"10.3109\/02844317809013000"},{"key":"R32-083517","doi-asserted-by":"crossref","unstructured":"Sober  AJ,   Day  CL Jr,   Fitzpatrick  TB,  et al:  Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients.   J Inv Dermatol 80s:  53s,1983-55s,","DOI":"10.1111\/1523-1747.ep12537168"},{"key":"R33-083517","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.134.4.381"},{"key":"R34-083517","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1992.01420040034005"},{"key":"R35-083517","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S"},{"key":"R36-083517","unstructured":"Tanabe  K,   Reintgen  D:   The role of sentinel lymph node mapping for melanoma.   Adv Surg 31:  79,1998-103,"},{"key":"R37-083517","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890440096014"},{"key":"R38-083517","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1968"},{"key":"R39-083517","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78608-6"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.2.568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:50:01Z","timestamp":1653515401000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.2.568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,15]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,1,15]]}},"alternative-id":["10.1200\/JCO.2001.19.2.568"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.2.568","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,15]]}}}